Products for Research Use Only

GW311616

CAT: 0804-HY-15891-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15891-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM[1].
CAS Number
198062-54-3
UNSPSC
12352005
Target
Elastase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/GW311616.html
Purity
99.30
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
O=C1[C@@H](C(C)C)[C@@](N(C(/C=C/CN2CCCCC2)=O)CC3)([H])[C@]3([H])N1S(=O)(C)=O
Molecular Formula
C19H31N3O4S
Molecular Weight
397.53
References & Citations
[1]Ohbayashi H, et al. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11 (7) :965-80.|[2]Jiang KL, et al. Neutrophil elastase and its therapeutic effect on leukemia cells. Mol Med Rep. 2015 Sep;12 (3) :4165-4172.|[3]Macdonald SJ, et al. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate. Bioorg Med Chem Lett. 2001 Apr 9;11 (7) :895-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Citation 01
Adv Sci (Weinh) . 2023 Aug;10 (24) :e2302613.|BMC Immunol. 2025 Aug 30;26 (1) :63.|Cell Immunol. 2020 Jun;352:104101.|EMBO Rep. 2023 Oct 9;24 (10) :e57032.|J Leukoc Biol. 2022 Dec;112 (6) :1427-1443.|Life Sci. 2020 Feb 1;242:117229.|Res Sq. 2025 Mar 30.|Sci Rep. 2017 Nov 30;7 (1) :16628.|Int Immunopharmacol. 2023 Jan:114:109537.|J Invest Dermatol. 2020 Jul;140 (7) :1371-1378.e3.